image1 (1).png
Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept
November 28, 2023 08:27 ET | Evaxion Biotech
Proof of Concept – Evaxion’s AI-Immunology™ platform demonstrates success in designing precision cancer vaccines in hematological cancers by targeting a novel class of antigensBroad Applicability –...
image1 (1).png
Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak
November 06, 2023 10:12 ET | Evaxion Biotech
EVX-01 is Evaxion’s lead clinical asset based upon its AI-Immunology™ platform and has recently published a phase 2 clinical update confirming former phase 1 resultsPrincipal investigator Professor...
New Logo.png
Provectus Biopharmaceuticals Announces Presentation of Preclinical PV-10 Vaccine Adjuvant Data at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
November 06, 2023 08:00 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical data from ongoing research on the potential use of investigational cancer immunotherapy...
image1 (1).png
Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01
October 31, 2023 11:15 ET | Evaxion Biotech
Initial EVX-01 Phase 2 data confirms the strong Phase 1 results After undergoing EVX-01 treatment, a significant and continuous tumor reduction was observed in a metastatic melanoma patient with...
website-logo (2).png
Cancer Vaccine Market Anticipates 11.8% CAGR Fueled by Government Funding and Research Initiatives - Study
October 23, 2023 06:50 ET |
New York, Oct. 23, 2023 (GLOBE NEWSWIRE) -- The cancer vaccine market is expected to witness growth with an estimated increase from US$ 6.8 Billion in 2022 to around US$ 20.2 Billion by the year...
Zion Market Research.jpg
[Latest] Global Cancer Vaccine Market Size Envisioned at USD 18.03 Billion by 2030, Increasing a CAGR of 11.6% | Healthcare Revolution
September 11, 2023 07:42 ET | Zion Market Research
NEW YORK, United States, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Cancer Vaccine Market By Type (Preventive Cancer Vaccines, And...
New Logo.png
Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
August 07, 2023 07:00 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical data from ongoing research on investigational cancer immunotherapy PV-10 (rose bengal...
Evaxion Logo.png
Evaxion unveils proprietary genetic adjuvant technology to boost the effect of DNA and mRNA vaccines
May 25, 2023 17:00 ET | Evaxion Biotech
Evaxion developed a genetic adjuvant technology that boosts the immune responses of viral, bacterial and cancer vaccinesPreclinically validated for both DNA and mRNA vaccines, and ready for clinical...
Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients
March 28, 2023 07:46 ET | Evaxion Biotech
New AI discovery de-risking the pipeline through faster validation and has potential to enter clinical Phase 1/2a in Q4 2023Phase 2b clinical trial reduced in size and expected to reach interim data...
Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)
March 14, 2023 16:30 ET | Evaxion Biotech
COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...